Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy

Annals of Hematology

Volumn 81, Issue 8, 2002, Pages 467-469

  Leo, E ^a   Kramer A ^a   Hochhaus, A ^b   Krasniqi, F ^a   Hehlmann, R ^b   Ho, A D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myelongenous leukemia; Drug side effect; Gangrene; Hydroxyurea

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA;

ADULT; ARTICLE; BLISTER; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE COURSE; DRUG WITHDRAWAL; GANGRENE; HUMAN; LEG ULCER; LONG TERM CARE; MALE; MYELOPROLIFERATIVE DISORDER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TOE;

ANTINEOPLASTIC AGENTS; GANGRENE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, CHRONIC; MALE; TIME FACTORS; TOES; TREATMENT OUTCOME;

EID: 0036938371     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0505-0     Document Type: Article

References (14)

1. (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 89:1616-1620
2. Cox C, Nowicky D, Young R (1997) Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: a case report and review of the literature. Ann Plast Surg 39:546-549
3. Daoud MS, Gibson LE, Pittelkow-MR (1997) Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 36:178-182
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
5. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Heinze B, Georgii A, et al. (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82:398-407
6. Honda K, Ando A, Endo M, Shimizu K, Higashihara M, Nitta K, Nihei H (1997) Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis 30:123-130
7. Kato N, Kimura K, Yasukawa K, Yoshida K (1999) Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. J Dermatol 26:56-62
8. Kido M, Tago O, Fujiwara H, Ito M, Niwano H (1998) Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostagladin E1 and pentoxifylline. Br J Dermatol 139:1124-1126
9. McDonald E, Marino C, Raftery T, Levine M (1991) Gangrene of the fingers secondary to myeloproliferative disease. Postgrad Med 90:115-118
10. Quaglino D, Torelli U, Emilia G (1966) A preliminary clinical evaluation of the therapeutic effects of hydroxyurea in patients with myelogenous leukaemia. Eur J Cancer 2:69-74
11. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, Kantarjian H (1999) Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35:109-118
12. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517-1536
13. Silver RT BP, Verma RS, Coleman M, Soper L, Gutfriend A (1990) Recombinant gamma-interferon has activity in chronic myeloid leukemia. Am J Clin Oncol 13:49-54
14. Yasuda N, Ohmori S, Usui T (2000) Hydroxyurea-induced gangrene of the toes in a patient with chronic myelogenous leukemia. Am J Hematol 63:103-104 f